ICAAC/IDSA 2008: Posters/Slides Library

Antiretrovirals in Development

• Long Term Vicriviroc Safety (PDF)
  Dunkle L, Greaves W, McCarthy M, et al.



• Response to Vicriviroc (VCV) in HIV-Infected Treatment-Experienced Subjects using an Enhanced Trofile HIV Co-receptor Tropism Assay: Reanalysis of ACTG 5211 Results (PDF)
  Su Z, Reeves J, Krambrink A, et al.

Antiretroviral Treatment Strategies

• Efficacy and Safety of Fosamprenavir + Ritonavir (FPV/r) 700mg/100mg Twice Daily (BID) Versus FPV/r 1400mg/100mg Once Daily (QD) with ABC/3TC QD over 24 Weeks (PDF)
  Carosi G, Lazzarin A, Stellbrink H, et al.



• Should Vitamin D Be Prescribed with Tenofovir/FTC? (H-2300)
  Childs K, Fishman S, Bateman K, et al.



• Switching from a 200mg-Ritonavir (RTV, r)-Boosted Fosamprenavir (FPV) Regimen (700mg/200mg BID or 1400mg/200mg QD) to a 100mg RTV-Boosted FPV Regimen (1400mg/100mg QD) Yields Similar Efficacy and Safety (PDF)
  Cohen C, DeJesus E, Lamarca A, et al.



• Simplification of Antiretroviral Therapy (ART) with Efavirenz (EFV)/Emtricitabine (FTC)/Tenofovir DF (TDF) Single-Tablet-Regimen vs. Continued Unmodified ART in Virologically-Suppressed, HIV-1-Infected Patients (PDF)
  DeJesus E, Young B, Flaherty J, et al.



• The 48-Week Efficacy and Safety of Switching to Fixed-Dose Efavirenz/Emtricitabine/Tenofovir DF in HIV-1-Infected Patients Receiving HAART (PDF)
  DeJesus E, Pozniak A, Gallant J, et al.



• 96-Week Efficacy/Safety Data Comparing Two Doses of Ritonavir (/r) to Boost Once-Daily (QD) Fosamprenavir (FPV), Used in Combination with Abacavir (ABC)/Lamivudine (3TC) (PDF)
  DeJesus E, Sloan L, Sension M, et al.



• Antiretroviral Treatment Simplification to Ritonavir-boosted Protease Inhibitor Monotherapy: Systematic Review and Meta-analysis
  Ena J, Pasquau F, Ruiz de Apodaca E, et al.



• Impact of Adding Maraviroc to HIV Patients with Undetectable Plasma RNA but are Non-CD4 Progressors (CD4~200 Cell/mm³) (PDF)
  Eng R, Perez G, Paez S, et al.



• Long-term Efficacy and Safety of Abacavir/Lamivudine (ABC/3TC) with Fosamprenavir + Ritonavir (FPV/r) Versus Lopinavir/Ritonavir (LPV/r) over 144 Weeks (PDF)
  Estrada V, Logue K, Domingo P, et al.



• Single Agent Therapy with Lopinavir/Ritonavir Durably Suppresses Viral Replication in ARV Naïve Patients: IMANI II - 96 Week Final Results (PDF)
  Gathe Jr. J, Yeh R, Mayberry C, et al.



• Durability of Virologic Response to Etravirine Is Not Affected by Time to Reach Virologic Response (PDF)
  Mills A, Cotte L, Smith S, et al.



• Three-year Efficacy of Lopinavir/ritonavir Monotherapy in the OK04 Trial (PDF)
  Pulido F, Delgado R, Arranz A, et al.

First-Line Antiretroviral Therapy

• When to Start Antiretroviral Therapy?
  Arribas J



• CD4+ Cell Restoration at 48 Weeks in the Maraviroc (MVC) Treatment-Naive (TN) MERIT Trial (PDF)
  Lazzarin A, Battegay M, Cooper D, et al.



• ARTEMIS: Efficacy and Safety of Darunavir/ritonavir (DRV/r) 800/100 mg Once-daily vs Lopinavir/ritonavir (LPV/r) in Treatment-naïve, HIV-1-infected Patients at 96 Wks (PDF)
  Mills A, Nelson M, Jayaweera D, et al.



• CASTLE: Atazanavir-Ritonavir vs Lopinavir-Ritonavir in Antiretroviral-Naïve HIV-1 Infected Patients: 96 Week Efficacy & Safety (PDF)
  Molina J, Andrade-Villanueva J, Echevarria J, et al.



• Six Abacavir/Lamivudine (ABC/3TC) Clinical Trials Show Robust Virologic Responses in ART-Naive H-1251 Patients for Baseline (BL) Viral Loads (VL) of ≥100,000 c/mL and <100,000 c/mL (PDF)
  Pappa K, Ha B, Brothers C, et al.



• Week 96 Virology Analysis of COL100758, a Study of Once-Daily (QD) Fosamprenavir (FPV) Boosted with 100 mg or 200 mg Ritonavir (/r) with Abacavir /Lamivudine in Antiretroviral Naïve HIV-infected Patients (PDF)
  Ross L, DeJesus E, Sloan L, et al.



• Atazanavir/Ritonavir (ATV/r) + Abacavir/Lamivudine (ABC/3TC) in Antiretroviral (ART)-Naive HIV-1 Infected HLA-B*5701 Negative Subjects Demonstrates Efficacy and Safety: the ARIES Trial (PDF)
  Squires K, Young B, DeJesus E, et al.



• Adherence in Antiretroviral Treatment-Naive Subjects Treated with Once Daily Atazanavir/ritonavir or Twice Daily Lopinavir/ritonavir, Both in Combination with Tenofovir/Emtricitabine: 48 Week Results from the CASTLE Study (PDF)
  Su J, Absalon J, Yang R, et al.



• Characterization of Virologic Failure (VF) Over 96 Weeks by Drug Resistance and Antiviral Response in ART Naïve Patients Receiving Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC) Each with Lopinavir/Ritonavir QD in the HEAT Study (PDF)
  Young B, Smith K, Patel P, et al.

Gender, Age and Race in HIV/HAART

• Long Term Follow-up of Teens with Perinatal HIV Infection after Disclosure of Diagnosis (PDF)
  Desai N, Abraham M, Cambridge-Phillip R, et al.



• Perceptions of Care by HIV-Infected Women in the United States (PDF)
  Hodder S, Aberg J, Feinberg J, et al.



• Race, Drug Use & Insurance Coverage in Use of HAART Among HIV Positive Women, 2002-2005 (PDF)
  Lillie-Blanton M, Stone V, Snow Jones A.



• Disparities in Comorbid Conditions among White and Black HIV/AIDS Patients in the United States National Hospital Discharge Survey (NHDS) (PDF)
  Oramasionwu C, Ryan L, Frei C.

Hepatitis/HIV Coinfection

• Low HCV Treatment Rates after a Liver Biospy
  Adeyemi O, Attar B, Huhn G, et al.



• HCV Treatment Eligibility in ERCHIVES (Electronically Retrieved Cohort of HCV Infected Veterans) (PDF)
  Butt A, McGinnis K, Skanderson M, et al.



• Hepatitis C Virus Infection and the Risk of Coronary Disease (PDF)
  Butt A, Xiaoqiang W, Budoff M, et al.



• Acute Hepatitis C: Management and New Epidemiology
  Fierer D



• Automated Detection of Acute Hepatitis C and Syphilis using Electronic Medical Record Data (PDF)
  Klompas M, Calderwood M, Lazarus R, et al.



• Economic Burden of HCV and HIV Co-infection Compared to HCV Alone in a Managed Care Population (PDF)
  Mitra D, Davis K, Beam C, et al.



• Does the Choice of peg-IFN Formulation Affect Safety or Efficacy in HIV/HCV-Coinfected Patients Receiving Weight-adjusted Ribavirin? (PDF)
  Moreno A, Quereda C, Perez-Elias M, et al.



• Twice Weekly Peg IFN-alpha-2a with Ribavirin Improves Early Viral Kinetics over Standard Therapy Among HIV/HCV Co-infected African American Patients
  Murphy A, Rozenberg L, Polis M, et al.



• Triglycerides, LDL Cholesterol and HOMA Score Predict the Virological Response in HIV/HCV Co-infected Patients Treated with PegInterferon alfa2a/Ribavirin (PegIFN/RBV)
  Nasta P, Gatti F, Cologni G, et al.



• HAART is Associated with a Lower Level of Hepatic Necroinflamatory Activity in HIV-HCV Coinfected Patients with CD4 > 350 at the Time of Liver Biopsy (PDF)
  Pascual Pareja J, Caminoa A, Larrauri J, et al.



• Sharp Decline in The Seroprevalence of Hepatitis C Virus Among HIV-infected Patients in Spain (PDF)
  Perez Cachafeiro S, Garcia L, Berenguer J, et al.



• Infectious Complications during peg-IFN plus Ribavirin in HIV-infected Patients with Chronic Hepatitis C (CHC) (PDF)
  Quereda C, Moreno A, Perez-Elias M, et al.



• Diagnostic Accuracy of Serum Hyaluronic Acid for Advanced Fibrosis/Cirrhosis in Patients Coinfected with HIV and HCV
  Resino S, Miralles P, Micheloud D, et al.



• Comparison of Transient Elastography, Apri, Forns, and Fib-4 for the Assessment of Liver Fibrosis in HIV/HCV-Coinfected Patients
  Sanchez-Conde M, Montes-Ramirez M, Gonzalez-Garcia J, et al.



• HCV in the HIV Infected Patient
  Thomas D

HIV and Pregnancy

• Use of Tenofovir Disoproxil Fumarate (TDF) in Pregnancy: Findings from the Antiretroviral Pregnancy Registry (APR) (PDF)
  Olmscheid B, Zhang S.



• Pregnancies Among HIV-Infected Women in Mississippi (PDF)
  Rana A, Gilani F, Beckwith C, et al.

Complications of HIV/HAART

• Recurrence or Worsening of AIDS-defining Opportunistic Infection (OI) Due to Immune Reconstitution Inflammatory Syndrome (IRIS) during HAART
  Achenbach C, Kitahata M.



• Liver Toxicity is Not Related to CD4+ Cell Counts in 221 Patients Switching to Nevirapine (NVP) Due to Simplification or Substitution Strategies (Toscana Study)
  Antela A, Ocampo A, Gomez R, et al.



• A High Risk of Hospitalization Immediately Follows HAART Initiation (PDF)
  Berry S, Gebo K, Moore R, et al.



• Rates of AIDS-Defining Opportunistic Conditions (ADOCs) and CD4 Cell Counts at ADOC Diagnosis in the U.S. HIV Outpatient Study (HOPS), 1994-2006 (PDF)
  Buchacz K, Baker R, Palella F, et al.



• HIV Infection and the Risk of Diabetes Mellitus (PDF)
  Butt A, McGinnis K, Rodriguez-Barradas M, et al.



• Prevalence of Pulmonary Hypertension in Asymptomatic HIV-infected Patients Receiving Antiretroviral Therapy (PDF)
  Byers D, Nayak G, Ferguson M, et al.



• Metabolic Profile and Cardiovascular Risk Factors in Latin American HIV Patients Receiving HAART (PDF)
  Cahn P, Leite O, Rosales A, et al.



• Risk Factors for Development of Anal Cancer in HIV-Infected Men
  Cole P, Leyden W, Silverberg M, et al.



• Reduction in AIDS Defining Events/Death (ADE/D) with Etravirine (ETR) Compared to Placebo (PL): Pooled DUET 48 Week Results (PDF)
  Haubrich R, Eron J, Thompson M, et al.



• Immune Reconstitution Syndrome in HIV-infected Patients with Cryptococcal Meningitis: A Prospective Study (PDF)
  Manosuthi W, Thongyen S, Chimsuntorn S, et al.



• Compliance with Breast Cancer Screening Guidelines in the HIV Clinic: A Quality Improvement Tool
  Patrozou E, Christaki E, Hicks L, et al.



• Comparative Analysis of HIV+ and HIV- Interaction with Testosterone on Bone Mineral Density (PDF)
  Raghunathan R, Sinacore J, Farano J, et al.



• The Impact of Tenofovir on Insulin Sensitivity and Lipids in Healthy Volunteers (PDF)
  Randell P, Jackson A, Zhong L, et al.



• Effect of Syphilis Co-Infection on Clinical Outcomes in HIV-Infected Persons
  Weintrob A, Gu W, Qin J, et al.

Second- and Third-Line HIV Treatment

• The Impact of Darunavir/ritonavir (DRV/r) & Raltegravir (RAL) in the Clinic: A New Era for Treatment-Experienced Patients? (PDF)
  Ayoub A, Goodrich J, Van Der Ryst E, et al.



• Adverse Event (AE) Profile of Maraviroc (MVC) in Treatment-experienced (TE) Patients Infected with R5 HIV-1
  Mugavero M, Lin H, Willig J, et al.

Pharmacokinetics

• A Pharmacokinetic (PK) Study to Evaluate an Interaction Bewteen Maraviroc (MVC) and Raltegravir (RAL) in Healthy Adults (PDF)
  Andrews E, Glue P, Labadie R, et al.



• Evaluation of the Pharmacokinetics (PK) and Safety of Etravirine (ETR) Administered QD and BID Following two weeks of Treatment with Efavirenz (EFV) in Healthy Volunteers (PDF)
  Boffito M, Jackson A, Lamorde M, et al.



• Pharmacokinetics (PK) and Pharmacodynamics (PD) of Etravirine (ETR) in Treatment-Experienced HIV-1 Infected Patients: Pooled 48-Week Results of DUET-1 and DUET-2 (PDF)
  Kakuda T, Peeters M, Corbett C, et al.



• The Effect of UGT2B7 Inhibition on the Steady-State Pharmacokinetics of UK-453,061 after Multiple-Dose Administration in Healthy Male Subjects
  Langdon G, Davis J, Labadie R, et al.



• Lack of a Pharmacokinetic Effect Between Steady-State Tipranavir/Ritonavir (TPV/r) and Single-Dose Valacyclovir in Healthy Volunteers (PDF)
  Sabo J, Cong X, Haas D, et al.

Monitoring Assays

• Performance Characteristics and Validation of the PhenoSense HIV Integrase Assay (PDF)
  Fransen S, Gupta S, Huang W, et al.



• Reanalysis of the MERIT Study with the Enhanced Trofile Assay (PDF)
  Saag M, Heera J, Goodrich J, et al.



• Validation of an Enhanced Sensitivity TrofileÔ HIV-1 Co-receptor Tropism Assay
  Trinh L, Han D, Huang W, et al.



• Weighted OBT Susceptibility Score (wOBTSS) is a Stronger Predictor of Virological Response at 48 Weeks than BL Tropism Result in MOTIVATE 1 and 2
  Valdez H, Lewis M, Delogne C, et al